American Refining Group Invests in Novvi to Accelerate Amyris Commercialization of Renewable Base Oil and Lubricant Platform

ARG Joins Amyris and Cosan with Equity Investment and Market Access to Accelerate Revenue Growth of Novvi High Performance, Sustainably Sourced, Renewable Lubricant Products CONSHOHOCKEN, Pa. and EMERYVILLE, Calif., July 19, 2016 (GLOBE NEWSWIRE) — American Refining Group, Inc. (‘ARG’) and Novvi LLC, a joint venture of Amyris, Inc. (Nasdaq:AMRS), an integrated renewable products company, and Cosan S.A., one of the largest corporations in Brazil, with businesses in energy, and infrastructure including lubricants, today announced that ARG has committed to a 33.3% equity investment into the joint venture. Both Amyris and Cosan will continue to hold share ownership stakes in Novvi, together with ARG. Novvi’s products and technology are recognized by the global lubricant market to deliver the best sustainable, high-performance solutions in a range of lubricant applications. ARG’s Bradford, Pennsylvania refinery, founded in 1881, is the oldest continuously operating refinery in North America. “Our launch of Novvi’s synthetic base oils has been embraced by manufacturers in a range of top-tier lubricant segments, across both automotive and industrial applications,” stated Jeff Brown, Novvi LLC’s CEO. “Our partnership with American Refining Group will help accelerate our growth by providing the necessary resources to ensure manufacturing, supply, and delivery capabilities to scale our business for volume and to meet customer expectations.” “ARG’s Bradford refinery was built on innovation and market leadership in 1881, and today we are seeing a change in the hydrocarbon economy, coupled with performance requirements in the base oil industry. This is an opportunity for ARG to lead the market once again — this time with a renewable product,” stated Tim Brown, Chief Executive Officer, American Refining Group,... read more

Amyris to Announce Second Quarter Financial Results on Thursday, August 4, 2016

EMERYVILLE, Calif., July 18, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS) will report financial results for the second quarter ended June 30, 2016 after market close on Thursday, August 4, 2016. The company will hold its quarterly conference call to discuss these results, as well as provide an update on the company’s business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 4, 2016. Conference Call: Thursday, August 4, 2016, 4:30 p.m. ET/1:30 p.m. PT Dial-in Number: (866) 516-3867 (U.S. & International) Access Code: 49059751 Audio Webcast: A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: http://investors.amyris.com. A replay of the webcast will be available on the Investor Relations section of the Company’s website approximately two hours after the conclusion of the call. About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com. Amyris and the Amyris logo are registered trademarks of Amyris, Inc.  ... read more

Ginkgo Bioworks and Amyris Partner to Accelerate Commercialization of Bio-Based Products

The leading organism company and the leading industrial bioscience company collaborate on combined portfolio of 70 cultured ingredients Teleconference to be Held Thursday, June 30, 2016 at 2:30 p.m. Eastern Time EMERYVILLE, Calif. and BOSTON, June 29, 2016 (GLOBE NEWSWIRE) — Ginkgo Bioworks, the organism company, and Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company announced a new partnership, which will enable the companies to jointly develop products more efficiently and cost effectively, accelerating time to market. This breakthrough biotech partnership creates clear leadership with a combined offering that has successfully introduced more bio-based products than any other company known in the field. The combined R&D capabilities of Ginkgo and Amyris put both partners at a significant advantage in the industry by leveraging the joint end-to-end technology platform. This partnership is expected to deliver more new cultured ingredients into the global market in the next three years than the total industry has achieved in the last 10 years. “Ginkgo and Amyris working together sets the gold standard for the industrial biotechnology industry,” said Jason Kelly, CEO of Ginkgo Bioworks. “Each company is seeing more customer demand for cultured ingredient partnerships than could be handled individually. By sharing our assets, expertise and experience we can offer more customers access to the industry-leading technology platform.” As part of the deal, Ginkgo Bioworks will broaden the capacity of Amyris’s strain engineering by providing access to its world-class foundry; Amyris will provide Ginkgo Bioworks scale up expertise and access to the world’s only commercial scale multi-product fermentation facility that has manufactured more cultured ingredients than any other known entity. Together, the two companies will... read more

Amyris Announces Long term, Multi-Million-Dollar Collaboration in Cosmetic Active Ingredients with Givaudan

EMERYVILLE, Calif., June 28, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced a new collaboration in the field of cosmetic active ingredients with Givaudan (SIX:GIVN), a leading global flavors and fragrances company. The two companies have been engaged in the research and development of proprietary fragrance ingredients for several years, and the significantly expanded partnership reinforces the diversity and value of Amyris’s R&D platform and manufacturing capabilities to customers demanding high performance, cultured ingredients. During the multiyear collaboration, Amyris will use its industry-leading strain engineering platform to design cosmetic active targets, and scale them up for global commercialization at Amyris’s manufacturing facility in Brotas, Brazil. The companies anticipate the launch of the target products in the coming years will demonstrate significant performance, cost and sustainability advantages over existing ingredients. “We are very pleased with our ongoing partnership with Amyris. As our company continues to look for innovative and sustainable solutions to availability and cost challenges, we are expanding the relationship to apply Amyris’s technology to a whole new field,” said Maurizio Volpi, President of Givaudan’s Fragrance Division. “This partnership will derive synergistic benefits from Givaudan’s deep understanding of the Active Beauty area and Amyris’s world class biotechnology platform.” “We are excited to be working with Givaudan to solve supply challenges and deliver sustainable innovation in cosmetic actives. We are very pleased with the Givaudan commitment to innovation and its leadership in delivering breakthrough advancements in Active Cosmetics,” said John Melo, Amyris President & Chief Executive Officer. “The collaboration validates, once again, our belief that Amyris offers its customers the fastest time to market from... read more

Takasago and Amyris Begin Commercialization of Novel Fragrance Product Being Introduced at the 2016 World Perfumery Congress

EMERYVILLE, Calif. and TOKYO, June 14, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and Takasago International Corporation (TYO:4914), a global leader in the creation of flavors and fragrances for consumer products, today announced the launch of an innovative new fragrance created from Amyris’s technology. The new fragrance is being launched at the 2016 World Perfumery Congress being held June 13-15, 2016 in Miami, Florida. Takasago is committed to using high performance, innovative and sustainably sourced materials that have a positive impact on its customers’ daily lives. The new fragrance was created as a result of a successful long-term relationship between Takasago and Amyris. “We are delighted to launch this important fragrance,” said Masayuki Mita, Senior Vice President of the Fragrance and Aroma Ingredients Division at Takasago. “Amyris’s unique technology platform enabled Takasago to take this molecule from concept to actual commercial production quickly while utilizing renewable resources, and we are pleased with the outcome.” “We are pleased with the success of this project with Takasago and our ability to support them in achieving their goals,” said John Melo, President & CEO of Amyris. “This partnership is yet another indication of why global market leaders come to Amyris to create innovative, high performance products while making their supply chain more sustainable.” About Takasago International Takasago International Corporation is a world leader in the flavour and fragrance industry. Founded in Japan in 1920, Takasago has developed flavours and fragrances for some of the world’s most successful food, beverage, fine fragrance, household and personal care products. Takasago is the only Asia-based global flavour and fragrance company specialising in... read more

Amyris Fuels First Delivery of New Airbus A350-900 Airplane for Cathay Pacific as Part of Two-Year Biojet Agreement

Two Year Committed Jet Fuel Supply Deal Demonstrating Continued Strong Farnesene Demand EMERYVILLE, Calif., June 13, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that, on May 29, 2016, Cathay Pacific commenced a two-year program of flights from Toulouse to Hong Kong using Amyris renewable jet fuel.  The initial 12-hour flight was the longest flight using a renewable jet fuel to date, further underpinning the ‘drop-in’ characteristics of Amyris Biojet fuels. Cathay took delivery of a new Airbus A350-900 that flew from the Airbus facility in Toulouse, France, to Hong Kong using a 10% biofuel jet blend provided by Amyris with the commercial and industrial support of Total S.A. The combination of the new airplane’s improvements in fuel efficiency (about 25% better than current aircraft) and the fuel’s properties resulted in an estimated 30% reduction in CO2 emissions according to Cathay when compared to comparable flights in recent-generation aircraft using fossil fuels. All of Cathay’s upcoming A350-900 aircraft deliveries over the next two years will use the Amyris/Total Biojet fuel. “Amyris and Total have a leading position in the biojet space and we are excited by the potential of this quality fuel to help us achieve the objective of growing our fleet, whilst minimizing our CO2 emissions per passenger,” said Jeff Ovens, Head of Cathay Pacific’s Biofuel Program.  “This two-year contract supporting regular, ultra long haul flights, will provide us with valuable experience as we move closer toward commercial scale volumes of biojet becoming available over the next few years.” “We are proud of our accomplishments with Total in support of the future sustainability... read more

Amyris Announces Collaboration with Johnson & Johnson Innovation for Biosynthetic Drug Discovery

Amyris’s µPharmTM Platform to be Used for Rapid Integrated Discovery and Production of Therapeutic Compounds EMERYVILLE, Calif., June 06, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has entered into a research agreement with a commercial license option with Janssen Biotech, Inc., part of Janssen Pharmaceutical Companies. Under the terms of the agreement, facilitated by Johnson & Johnson Innovation, the collaboration will use Amyris’s µPharmTM platform technology to develop a customized library of natural and natural-like compounds to test against Janssen’s therapeutic target. Nature has been a great source for therapeutics, ranging from antibiotics to statins that lower cholesterol levels; however, Nature’s potential is often under-utilized due to scarcity or unavailability. Amyris’s µPharm platform technology enables an integrated discovery and production process for therapeutic compounds. It not only provides access to scarce natural compounds, but also creates new diversity based on natural compound scaffolds. “We’re pleased to add another strong partner to our collaboration portfolio and this agreement is consistent with our overall business model of upfront development investment by a partner and an opportunity for a long term revenue stream following successful commercialization,” said Cynthia Bryant, Amyris Senior Vice President Corporate Development & Collaborations. “This technology opens a new area of compounds that have never been accessible for new drug discovery.” Over the course of the agreement, Amyris will utilize the µPharm platform technology to develop a library of natural and natural-like compounds and test the efficacy of those compounds in vivo for hits against Janssen’s identified target. This is a different approach than traditional high throughput screening, which typically... read more

Amyris to Participate in June 2016 Investor Conferences

EMERYVILLE, Calif., May 27, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in June 2016 and provide an update on new partnerships and growth opportunities as part of its business plan for the year. Cowen and Company Technology, Media & Telecom Conference “Industrial Biotechnology — Diving into Next-Gen Chemicals and Fuels” panel discussion June 1, 2016 8:45-9:25 a.m. Eastern Time Lotte New York Palace Hotel, New York City Stifel 2016 Technology, Internet & Media Conference June 7, 2016 9:45-10:15 a.m. Pacific Time Fairmont Hotel, San Francisco Singular Research 11th Annual “Best of the Uncovereds” Spring Select Conference — Discovery Track June 9, 2016 2:30-3:15 p.m. Pacific Time Hilton Financial District Hotel, San Francisco Live audio webcasts of the Stifel and Singular presentations (replays available for 90 days) will be available by visiting the investor relations section of the company’s website at http://investors.amyris.com. Due to the format of the Cowen event, no webcast will be available. About Amyris Amyris is the integrated renewable products company that’s enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com. Amyris and the Amyris logo are registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.  ... read more

Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership

EMERYVILLE, Calif., May 20, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and South Korea-based CJ CheilJedang Corporation (“CJ”)(KRX:097950), today announced that the companies have signed a Memorandum of Understanding (MOU) to support large-scale manufacturing of Amyris’s farnesene in existing CJ facilities. The arrangement described in the MOU would enable Amyris to utilize CJ’s state of the art manufacturing capacity while minimizing the capital investment necessary to support projected near- and mid-term demand for product applications using farnesene. The partnership is also expected to include the opportunity for CJ Bio (division of CJ CheilJedang) to market select Amyris products in Asian markets as well as the potential for Amyris to develop several products for CJ Bio. The companies are targeting completing a definitive agreement by the first week of August 2016. “We are very pleased with the innovative approach of CJ CheilJedang, to support quickly ramping up our farnesene capacity with minimal capital investment and with the collaborative partnership to market some of our products in Asia,” said John Melo, President & CEO of Amyris. “This partnership completes our commercialization strategy by providing us the ability to meet our farnesene demand from our current partners without new investment from Amyris and underpins our expected capacity needs to meet farnesene demand that would require building 3-4 new plants the size of our Brotas facility by 2020. We are also pleased with the opportunity to partner with CJ for sales efforts in Asia and the potential to collaborate on new products that meet the needs of their existing customers.” “We are excited to partner with Amyris and leverage... read more

Amyris to Participate in Upcoming Investor Conferences in May 2016

EMERYVILLE, Calif., May 11, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in May 2016. Oppenheimer Emerging Growth ConferenceMay 17, 2016Sofitel Hotel, New York City Naseba Investors ConferenceMay 24, 2016Dubai, United Arab Emirates During each of these events management will meet with new investors in one-on-one only meetings.  Due to the format of these events, no webcast will be available. About Amyris Amyris is the integrated renewable products company that’s enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com. Amyris and the Amyris logo are registered trademarks of Amyris, Inc. Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 investor@amyris.com... read more

Join our Mailing List

Sign Up